Trial Profile
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Aug 2018
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors UCB
- 05 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Apr 2013 Planned end date changed from 1 Mar 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 17 Aug 2012 Actual initiation date Jul 2012 added as reported by ClinicalTrials.gov.